Atopic Dermatitis: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797442
  • Drug Pipelines
  • 184 pages
  • Datamonitor Healthcare
1 of 3
Dupilumab is expected to be the first biologic approved for atopic dermatitis, offering a novel treatment option for the most severe patients and driving a strong CAGR of 15.6% during the 2015-24 forecast period.

This report addresses the following questions:

- Where is the untapped commercial opportunity in the atopic dermatitis market?
- How will the late-phase candidates dupilumab and crisaborole fit into the existing atopic dermatitis treatment algorithm?
- What do surveyed dermatologists consider to be the greatest unmet needs in atopic dermatitis?
- What role does pricing and reimbursement play in prescribing for atopic dermatitis and what impact will the launch of new therapies have on this?
- How do prescribing patterns change as disease severity increases?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: ATOPIC DERMATITIS

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- crisaborole
- dupilumab
- Elidel (pimecrolimus)
- Elocon (mometasone furoate)
- Protopic (tacrolimus)
- Primary Research Methodology

TREATMENT: ATOPIC DERMATITIS

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Persistence and Compliance
- Unmet Needs in Atopic Dermatitis
- Prescribing Influences
- Pipeline Drugs and Future Treatment

EPIDEMIOLOGY: ATOPIC DERMATITIS

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: ATOPIC DERMATITIS

- Executive Summary
- Product Overview
- Product profile: Elidel
- Product profile: Elocon
- Product profile: Medrol
- Product profile: Protopic
- Product profile: Toctino

PIPELINE: ATOPIC DERMATITIS

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): crisaborole
- Product profile (late stage): dupilumab
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll